S.B. Kim

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

Peter Schmid, Roberto Salgado, Y.H. Park et al. · Annals of Oncology · 2020 · 423 citations

Phase 1B, Breast Oncology, Oncology +9

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

Giuseppe Curigliano, Susana Banerjee, Andrés Cervantes et al. · Annals of Oncology · 2020 · 303 citations · Full text

Health Policy, Medicine, Global Health +9

ESO–ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

Shani Paluch–Shimon, Fátima Cardoso, Ann H. Partridge et al. · Annals of Oncology · 2022 · 197 citations · Full text

Breast Oncology, Medicine, Gynecology +8

Prevention of uncuffed hemodialysis catheter-related bacteremia using an antibiotic lock technique: A prospective, randomized clinical trial

Sung‐Han Kim, Kwanju Song, Jai Won Chang et al. · Kidney International · 2005 · 112 citations

Hemodialysis, Randomized Clinical Trial, Antibiotics +11

A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis

Adam Brufsky, S.B. Kim, Zanete Zvirbule et al. · Annals of Oncology · 2021 · 84 citations · Full text